Bristol-Myers Squibb: Bristol Myers Squibb's phase 3 ODYSSEYHCM trial of Camzyos to treat patients with symptomatic NYHA class IIIII nHCM fails to meet its dual primary endpoints

Bristol Myers Squibb announced the phase 3 ODYSSEY─HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II─III non─